News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
ICR calls for change to bring immunotherapies to more cancer patients
Major changes to the way immunotherapy drugs are researched and evaluated are essential if they are to become successful treatment options for many more types of cancers, leading cancer experts are warning.
ICR is top-ranked university for invention income for seventh consecutive year
The Institute of Cancer Research, London, has again been the most successful academic institution in the UK at making income from its intellectual property – for the seventh successive year.
ICR Discovery Club gives members a virtual glimpse into the cancer genetics lab
Members of the ICR’s Discovery Club were given an exclusive insight into how researchers sample, process and analyse tumour cells in the lab, as part of the ICR’s first virtual event for our donors.
Study seeks to find out why black men develop prostate cancer at twice the rate of other men
A first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men in the UK.
New study sheds light on the best drug choices for some patients with advanced breast cancer
Patients with metastatic breast cancer carrying a particular mutation fare better on one form of hormone therapy than another and can be identified using a blood test, according to a new study.
-547x410.png?sfvrsn=6c38d100_2 "cell-division-(green-4-3) 547x410")
Scientists reveal important role for ‘workhorse’ of cell division
A new study shows how a crucial protein, which acts as trigger for cell division, helps release another key protein from the cell’s ‘control centre’.
New drug targeting high-risk children’s cancer is ready for trials
A new drug that has passed safety tests in adults shows the potential to be effective against the aggressive childhood cancer neuroblastoma, scientists have found.
Aggressive childhood cancer could be treated by combining DNA-damage targeting drugs
An aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently used in the treatment of colon and ovarian cancer, a study led by researchers at The Institute of Cancer Research, London, suggests.
-content.tmb-hbmobile.jpg?Culture=en&sfvrsn=fec93f9d_2 "Dispensing medicines for a clinical trial (Jan Chlebik for the ICR, 2014) content")
New drug targeting DNA repair shows promise in range of advanced cancers
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.
ICR and Cancer Research UK spinout company Monte Rosa Therapeutics raises USD96m in ‘Series B’ Financing
Monte Rosa Therapeutics, a company originally formed as a spinout from Cancer Research UK-funded drug discovery research at the ICR, in collaboration with Versant’s drug discovery engine Ridgeline Therapeutics, has closed a $96m ‘series B’ financing from investors to support the further development of its drug pipeline.
Navigating our way through a new era of fundraising
Lara Jukes is the Director of Development at the ICR. Here she shares her personal thoughts on the impact the coronavirus pandemic has had on the charity, the life-saving research it supports, and those who benefit from it.
How a decade of research progress offers hope to children with neuroblastoma
Researchers at the ICR are working hard to improve the outlook for children with cancer. Here we look back on a decade of discoveries made possible by the support of the parent-led charity Christopher’s Smile, which was founded just over 10 years ago.
